Phantom-based investigation of block sequential regularised expectation maximisation (BSREM) reconstruction for zirconium-89 PET-CT for varied count levels

Phantom-based investigation of block sequential regularised expectation maximisation (BSREM) reconstruction for zirconium-89 PET-CT for varied count levels

Background: Zirconium-89 (Zr-89) PET tracers have become increasingly significant in the field of nuclear medicine due to their 3-day physical half-life, allowing for the study of dynamic biological processes over relatively long timeframes. To date there has been limited publication of studies focu...

Descripció completa

Dades bibliogràfiques
Autors principals:	Bonney, LM, Walker, MD, McGowan, DR
Format:	Journal article
Idioma:	English
Publicat:	SpringerOpen 2025

Ítems similars

Phantom-based investigation of block sequential regularised expectation maximisation (BSREM) reconstruction for zirconium-89 PET-CT for varied count levels
per: Lara M. Bonney, et al.
Publicat: (2025-02-01)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
per: Kamil G. Laban, et al.
Publicat: (2019-07-01)

Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications
per: Valentina Albanese, et al.
Publicat: (2024-05-01)

Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging
per: Laure Badier, et al.
Publicat: (2024-06-01)

Impact of PET data driven respiratory motion correction and BSREM reconstruction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS)
per: Virginia Liberini, et al.
Publicat: (2021-01-01)

Recent Advances in Zirconium-89 Chelator Development
per: Nikunj B. Bhatt, et al.
Publicat: (2018-03-01)

Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318
per: Elaine M. Jagoda, et al.
Publicat: (2023-01-01)

Scaling-down antibody radiolabeling reactions with zirconium-89
per: Knight, JC, et al.
Publicat: (2016)

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89.
per: Nikunj B Bhatt, et al.
Publicat: (2017-01-01)

Sustainable development : counting the cost - maximising the value
Publicat: (1995)

DYNAMIC PET RECONSTRUCTION ALGORITHMS USING EMPIRICAL MODE DECOMPOSITION REGULARISATION
per: McLennan, A, et al.
Publicat: (2009)

Maximising expected value under axiological uncertainty
per: Riedener, S
Publicat: (2015)

Microscale radiolabelling of antibodies with zirconium-89 for positron emission tomography
per: Knight, J, et al.
Publicat: (2015)

Yttrium-90 quantitative phantom study using digital photon counting PET
per: Joey Labour, et al.
Publicat: (2021-07-01)

Spatio-temporal reconstruction of dPET data using complex wavelet regularisation.
per: McLennan, A, et al.
Publicat: (2009)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
per: Ahmed M. A. Mostafa, et al.
Publicat: (2023-04-01)

Automated synthesis of [89Zr]ZrCl4, [89Zr]ZrDFOSquaramide-bisPh(PSMA) and [89Zr]ZrDFOSquaramide-TATE
per: Asif Noor, et al.
Publicat: (2024-05-01)

89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
per: Mohammed Al-Zubaidi, et al.
Publicat: (2022-04-01)

Utility Maximisation: Non-concave utility and non linear expectation
per: Cheung, H
Publicat: (2011)

The expected one /
per: 444670 McGowan, Kathleen
Publicat: (2006)

In Vitro and In Vivo Characterization of <sup>89</sup>Zirconium-Labeled Lintuzumab Molecule
per: Kevin J. H. Allen, et al.
Publicat: (2022-10-01)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
per: Aiman H. Alnahwi, et al.
Publicat: (2020-05-01)

PET/SPECT Test Phantom
per: Shah, Sayed Inayatullah
Publicat: (2010)

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
per: Elaine M. Jagoda PhD, et al.
Publicat: (2019-04-01)

Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe
per: Derrek A. Heuveling, et al.
Publicat: (2018-02-01)

Regularised empirical orthogonal functions†
per: Abdel Hannachi
Publicat: (2016-10-01)

Tracking of group‐housed pigs using multi‐ellipsoid expectation maximisation
per: Mateusz Mittek, et al.
Publicat: (2018-03-01)

Personalised treatment assignment maximising expected benefit with smooth hinge loss
per: Shixue Liu, et al.
Publicat: (2017-01-01)

Expectation-maximisation for speech source separation using convolutive transfer function
per: Xiaofei Li, et al.
Publicat: (2019-01-01)

Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate
per: Falguni Basuli, et al.
Publicat: (2024-04-01)

Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
per: Denis R Beckford Vera, et al.
Publicat: (2018-01-01)

Modified PET / SPECT cylindrical phantom
per: Sayed, Inayatullah Shah, et al.
Publicat: (2007)

Multimodal phantoms for clinical PET/MRI
per: Eve Lennie, et al.
Publicat: (2021-08-01)

Utility Maximisation as a Pathway for Maximisation of Happiness
per: Siddhartha Mitra
Publicat: (2013-07-01)

Dense Structural Expectation Maximisation with Parallelisation for Efficient Large−Network Structural Inference
per: Fogelberg, C, et al.
Publicat: (2013)

Constrained expectation maximisation algorithm for estimating ARMA models in state space representation
per: Andreas Galka, et al.
Publicat: (2020-05-01)

Complexity of Products: The Effect of Data Regularisation
per: Orazio Angelini, et al.
Publicat: (2018-10-01)

Modelling of Size Effect with Regularised Continua
per: H. Askes, et al.
Publicat: (2004-01-01)

Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging
per: Pamela Leland, et al.
Publicat: (2023-06-01)

Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
per: Marc C. Huisman, et al.
Publicat: (2021-08-01)